AstraZeneca, Joslin Diabetes Center deal

AstraZeneca’s MedImmune LLC biologics unit and the center partnered to develop candidates to treat metabolic disorders, including diabetes and obesity. Under the three-year deal, MedImmune will be responsible for providing research funding and both partners will work together to develop new candidates. ...